Health Condition 1: M321- Systemic lupus erythematosus withorgan or system involvement
Conditions
Interventions
Intervention1: DAPAGLIFLOZIN 10MG ONCE DAILY FOR 12 MONTHS: DAPGLIFLOZIN 10MG ONCE DAILY WILL BE GIVEN ALONG WITH STANDARD OF CARE TREATMENT
Control Intervention1: STANDARD OF CARE TREATMENT: INDUCTIO
Sponsors
DR MANISH RATHI
Eligibility
Inclusion criteria
Inclusion criteria: ALL NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS WITH BIOPSY PROVEN LUPUS NEPHRITIS (CLASS III,IV,V,III+V,IV+V) ARE ELIGIBLE IF THEY ARE ABOVE 18 YEARS OF AGE
Exclusion criteria
Exclusion criteria: 1. PATIENTS HAVING PULMONARY ALVEOLAR HEMMORHAGE 2. PATIENTS WITH NEUROPSYCHIATRIC SLE 3. PATIENT WITH RAPIDLY PROGRESSIVE RENAL FAILURE 4. PATIENTS WHO ARE ON HEMODIALYSIS 5. PATIENTS WITHH eGFR LESS THAN 25 ml/min /1.73 m2 6. PATIENTS WITH BASELINE CREATININE MORE THAN 3 mg/dl 7. PATIENTS UNWILLING TO GIVE CONSENT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TREATMENT RESPONSE AFTER 6 MONTHS AS PER KDIGO GUIDELINES WITH SERUM CREATININE , 24HOUR URINE PROTEINTimepoint: TREATMENT RESPONSE AFTER 6 months of intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| FREQUENCY OF URINARY TRACT INFECTIONS IN BOTH ARMSTimepoint: FOLLOWED UP EVERY MONTHLY FOR 6 MONTHS AND 3 MONTHLY UNTIL 12 MONTHS;NUMBER OF LUPUS FLARES IN BOTH ARMSTimepoint: FOLLOWED UP EVERY MONTHLY TILL 6 MONTHS AND 3 MONTHLY UNTIL 12 MONTHS;NUMBER OF SLE RELATED COMPLICATIONS AND DEATHS IN EACH ARMSTimepoint: FOLLOWED UP MONTHLY FOR 6 MONTHS AND 3 MONTHLY UNTIL 12 MONTHS | — |
Countries
India
Contacts
Public ContactDr NIRANJAN A V
PGIMER CHANDIGARH
Outcome results
None listed